UiPath Inc vs Koninklijke Philips NV — how do they compare? UiPath Inc trades at $13.33 (market cap $6.91B), while Koninklijke Philips NV trades at $24.38 (market cap $23.52B). The key difference: Koninklijke Philips NV is far larger — about 3.4× UiPath Inc's market cap, and Koninklijke Philips NV pays a 4.17% dividend while UiPath Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold UiPath Inc for 139 Days and Koninklijke Philips NV for 84 Days on average.
| PATH | PHG | |
|---|---|---|
Market Cap | $6.91B | $23.52B |
Volume | 34,321,250 | 1,635,069 |
Sector | Technology | Health |
52-Week High | $19.29 | $32.91 |
52-Week Low | $9.38 | $23.81 |
Typical Hold Time | 139 Days | 84 Days |
Enterprise Value | $5.70B | $29.87B |
Dividend Yield | — | 4.17% |
Signals from Pluang's Aura AI — not financial advice
UiPath (PATH) trades at $13.07, down 0.23% on the day, amid a bearish technical signal and mixed earnings history. The company shows improving fundamentals with revenue growing from $1.43B in 2025 to a projected $1.7B in 2026, while net income is expected to turn positive. Recent news highlights AI partnerships and product innovations, but the stock faces headwinds from cautious analyst sentiment and technical resistance.
The outlook for PATH is cautiously optimistic, with strong revenue growth and a path to profitability offering upside potential, but risks include execution challenges and competitive pressures. The consensus price target of $15.13 suggests moderate upside from current levels, though investor sentiment remains divided.
PHG trades at $24.09, down 0.25% on the day, with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with net income turning positive to $895M in 2025 after previous losses, supported by strong operational cash flow of $1.17B. Recent news highlights product innovations including new CT systems and AI healthcare tools, while institutional investors like Bank of America and Arrowstreet Capital have increased positions.
PHG presents a mixed outlook with solid profitability recovery but technical weakness. The stock offers value at reasonable valuations (P/E 18.84, P/S 1.18) and analyst consensus leans Hold (63.64%). Key risks include cybersecurity threats (Reuters, 2026-08-13) and debt levels, while opportunities lie in healthcare technology expansion and Exor's potential increased stake to 22% (Reuters, 2026-08-11).
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →